Diabetes & Metabolic Syndrome-Clinical Research & Reviews最新文献

{"title":"Changes in serum lipids following consumption of coconut oil and palm olein oil: A sequential feeding crossover clinical trial","authors":"Hasinthi Swarnamali ,&nbsp;Priyanga Ranasinghe ,&nbsp;Ranil Jayawardena","doi":"10.1016/j.dsx.2024.103070","DOIUrl":"10.1016/j.dsx.2024.103070","url":null,"abstract":"<div><h3>Background</h3><p>High incidence of cardiovascular disease (CVD) in South Asia is linked to genetic predisposition and diets high in saturated fatty acids (SFAs). Increased CVD prevalence correlates with rising palm oil consumption in some South Asian countries, where coconut oil and palm olein oil are primary SFA sources.</p></div><div><h3>Objective</h3><p>Compare the effects of coconut oil and palm olein oil on serum lipoprotein lipids and biochemical parameters in healthy adults.</p></div><div><h3>Methods</h3><p>A sequential feeding crossover clinical trial with two feeding periods of 8 weeks each was conducted among 40 healthy adults. Participants were provided palm olein oil in the first feeding period followed by coconut oil with a 16-week washout period in between. The outcomes measured were the difference in serum low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-C), TC/HDL-C ratio, triglycerides (TG), very-low-density lipoprotein cholesterol (VLDL-C), fasting plasma glucose (FPG), and liver enzymes.</p></div><div><h3>Results</h3><p>Thirty-seven participants completed the study. LDL-C decreased by 13.0 % with palm olein oil (p &lt; 0.001) and increased by 5.6 % with coconut oil (p = 0.044), showing a significant difference (p &lt; 0.001). TC decreased by 9.9 % with palm olein oil (p &lt; 0.001) and increased by 4.0 % with coconut oil (p = 0.044).</p></div><div><h3>Conclusion</h3><p>Palm olein oil consumption resulted in more favorable changes in lipid-related CVD risk factors (TC, LDL-C, TC:HDL-C, and FPG) compared to coconut oil.</p><p>Clinical Trial Registry number and website where it was obtained: (SLCTR/2019/034); <span>https://slctr.lk/trials/slctr-2019-034</span><svg><path></path></svg>.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 6","pages":"Article 103070"},"PeriodicalIF":4.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141564839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-trimester fasting plasma glucose as a predictor of subsequent gestational diabetes mellitus and adverse fetomaternal outcomes: A systematic review and meta-analysis","authors":"Saptarshi Bhattacharya ,&nbsp;Lakshmi Nagendra ,&nbsp;Deep Dutta ,&nbsp;Sunetra Mondal ,&nbsp;Sowrabha Bhat ,&nbsp;John Michael Raj ,&nbsp;Hiya Boro ,&nbsp;A.B.M. Kamrul-Hasan ,&nbsp;Sanjay Kalra","doi":"10.1016/j.dsx.2024.103051","DOIUrl":"https://doi.org/10.1016/j.dsx.2024.103051","url":null,"abstract":"<div><h3>Background</h3><p>The implication of intermediately elevated fasting plasma glucose (FPG) in the first trimester of pregnancy is uncertain.</p></div><div><h3>Purpose</h3><p>The primary outcome of the meta-analysis was to analyze if intermediately elevated first-trimester FPG could predict development of GDM at 24–28 weeks. The secondary outcomes were to determine if the commonly used FPG cut-offs 5.1 mmol/L (92 mg/dL), 5.6 mmol/L (100 mg/dL), and 6.1 mmol/L (110 mg/dL) correlated with adverse pregnancy events.</p></div><div><h3>Data sources</h3><p>Databases were searched for articles published from 2010 onwards for studies examining the relationship between first-trimester FPG and adverse fetomaternal outcomes.</p></div><div><h3>Study selection</h3><p>A total of sixteen studies involving 115,899 pregnancies satisfied the inclusion criteria.</p></div><div><h3>Data extraction and data synthesis</h3><p>Women who developed GDM had a significantly higher first-trimester FPG than those who did not [MD 0.29 mmoL/l (5 mg/dL); 95 % CI: 0.21–0.38; P &lt; 0.00001]. First-trimester FPG ≥5.1 mmol/L (92 mg/dL) predicted the development of GDM at 24–28 weeks [RR 3.93 (95 % CI: 2.67–5.77); P &lt; 0.0000], pre-eclampsia [RR 1.55 (95%CI:1.14–2.12); P = 0.006], gestational hypertension [RR1.47 (95%CI:1.20–1.79); P = 0.0001], large-for-gestational-age (LGA) [RR 1.32 (95%CI:1.13–1.54); P = 0.0004], and macrosomia [RR1.29 (95%CI:1.15–1.44); P &lt; 0.001]. However, at the above threshold, the rates of preterm delivery, lower-segment cesarean section (LSCS), small-for gestational age (SGA), and neonatal hypoglycemia were not significantly higher. First-trimester FPG ≥5.6 mmol/L (100 mg/dL) correlated with occurrence of macrosomia [RR1.47 (95 % CI:1.22–1.79); P &lt; 0.0001], LGA [RR 1.43 (95%CI:1.24–1.65); P &lt; 0.00001], and preterm delivery [RR1.51 (95%CI:1.15–1.98); P = 0.003], but not SGA and LSCS.</p></div><div><h3>Limitations</h3><p>Only one study reported outcomes at first-trimester FPG of 6.1 mmol/L (110 mg/dL), and hence was not analyzed.</p></div><div><h3>Conclusion</h3><p>The risk of development of GDM at 24–28 weeks increased linearly with higher first-trimester FPG. First trimester FPG cut-offs of 5.1 mmol/L (92 mg/dL) and 5.6 mmol/L (100 mg/dL) predicted several adverse pregnancy outcomes.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 6","pages":"Article 103051"},"PeriodicalIF":10.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141249892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring extended reality for diabetes education & self-management – A bibliometric analysis from 1999 to 2023","authors":"Megha Nataraj ,&nbsp;G Arun Maiya ,&nbsp;Shankar Prasad Nagaraju ,&nbsp;Barkur Ananthakrishna Shastry ,&nbsp;Shivashankara K. N ,&nbsp;Sahana Shetty ,&nbsp;Sohini Raje","doi":"10.1016/j.dsx.2024.103071","DOIUrl":"https://doi.org/10.1016/j.dsx.2024.103071","url":null,"abstract":"<div><h3>Background</h3><p>Diabetes Mellitus (DM) has emerged as a rapidly growing non-communicable disease (NCD) across developed &amp; developing countries. People with diabetes mellitus experience health implications. They develop associated microvascular complications such as neuropathy, nephropathy &amp; retinopathy and macro-vascular complications like coronary artery disease, stroke, amputations etc. These complications increase the socio-economic burden of people living with diabetes. Self-management of diabetes through education is a strong tool that remains under-utilized in clinical settings. The objective of the present study was to explore the role of extended reality for diabetes education &amp; self-management.</p></div><div><h3>Methodology</h3><p>The present study is a bibliometric analysis performed on the Scopus database with keywords: diabetes education, self-management, extended reality, virtual reality, augmented reality, mixed reality, and Boolean operators AND, OR. The search period ranged from inception till 4^th July 2023 with restriction to English language articles. A total of 89 documents were identified in Scopus under multiple domains such as Engineering, Medicine, Health Professions, Nursing among others. The data was exported to the VOS Viewer software for network analysis.</p></div><div><h3>Results</h3><p>Out of the total 89 documents, 45-original research, 26-review, 12-conference paper, 3-book, 2-book chapters &amp; 1-note. The highest publications were from the Medicine category. The year of publication of the included documents ranged from 1999 till 2022. The network analysis was performed to explore the association between the included studies (co-authorship, co-occurrence, citation analysis, bibliographic coupling).</p></div><div><h3>Conclusion</h3><p>The network analysis found the USA to be the leading publisher and the National Institute of Health (NIH) to be the leading funding source. There is limited evidence and a strong future scope to strengthen research productivity on extended reality for diabetes education &amp; self-management.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 6","pages":"Article 103071"},"PeriodicalIF":4.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141582776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seasonal differences in physical activity, sedentary behaviour, and sleep patterns in people with type 1 diabetes in Kuwait","authors":"Ebaa Al-Ozairi ,&nbsp;Mohammad Irshad ,&nbsp;Abdullah Al-Ozairi ,&nbsp;Jumana Al-Kandari ,&nbsp;Etab Taghadom ,&nbsp;Anisha Varghese ,&nbsp;Amira Megahed ,&nbsp;Amal Abdullah ,&nbsp;Sahar Murad ,&nbsp;Stuart R. Gray","doi":"10.1016/j.dsx.2024.103046","DOIUrl":"10.1016/j.dsx.2024.103046","url":null,"abstract":"<div><h3>Aims</h3><p>The main aim of the current study was to measure physical activity, sedentary behaviors and sleep levels across the different seasons in people with type 1 diabetes in Kuwait.</p></div><div><h3>Methods</h3><p>A prospective cross-sectional study was conducted from August 2021 to September 2022. Physical activity and sleep metrics were measured over a 7-day period with a wrist-worn accelerometer (GENEActiv). Overall physical activity was measured as a Euclidean Norm Minus One in milli gravitational units (m<em>g</em>). Accelerometer metrics were compared across the seasons and between the sex.</p></div><div><h3>Results</h3><p>A total of 784 people with type 1 diabetes participated. Mean daily physical activity was 25.2 m<em>g</em> (SD = 7.3). Seasonal differences were seen in overall physical activity (p = 0.05), inactivity (p = 0.04), light activity (p = 0.001), the intensity gradient (p = 0.001) and sleep efficiency (p = 0.02). Poorer metrics were generally seen in Spring and Summer. Overall physical activity, moderate and vigorous physical activity, and inactivity were significantly higher in males compared to females (p ≤ 0.02). Females had a longer sleeping duration (p = 0.02), and higher sleep efficiency (p = 0.04) and light physical activity (p = 0.01). Overall physical activity and the intensity gradient were negatively associated with HbA1c (both p = 0.01).</p></div><div><h3>Conclusions</h3><p>Physical activity levels were generally low and sleep poor in people with type 1 diabetes in Kuwait and these varied by sex and season. The current data are useful to target and develop interventions to improve physical activity and glycemic control.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 6","pages":"Article 103046"},"PeriodicalIF":10.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1871402124001073/pdfft?md5=56d43c113b8060a50113c5e6a71e8227&pid=1-s2.0-S1871402124001073-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141142325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to lowering plasma glucose is characterised by decreased oxyntomodulin: Results from a randomised controlled trial","authors":"Yutong Liu,&nbsp;Wandia Kimita,&nbsp;Sakina H. Bharmal,&nbsp;Maxim S. Petrov","doi":"10.1016/j.dsx.2024.103052","DOIUrl":"10.1016/j.dsx.2024.103052","url":null,"abstract":"<div><h3>Background</h3><p>With the prevalence of diabetes reaching an epidemic level, there is a growing interest in the investigation of its remission. Proglucagon-derived peptides (PGDP) have been shown to have a glucose-regulating effect. However, whether they play a role in diabetes remission remains poorly understood.</p></div><div><h3>Aim</h3><p>To investigate changes in plasma levels of PGDP in glycaemic responders versus non-responders.</p></div><div><h3>Methods</h3><p>The study was a randomised placebo-controlled trial comprising 18 adults with prediabetes (registered at <span>www.ClinicalTrials.gov</span><svg><path></path></svg> as NCT03889210). Following an overnight fast, participants consumed ketone β-hydroxybutyrate (KEβHB)-supplemented beverage and placebo beverage in crossover manner. Serial blood samples were collected from baseline to 150 min at 30-min intervals. The endpoints were changes in glucagon-like peptide-1 (GLP-1), glicentin, oxyntomodulin, glucagon, and major proglucagon fragment (MPGF). Participants were stratified into the 'responders' and ‘non-responders' subgroups based on their glycaemic changes following the ingestion of KEβHB. The area under the curve (AUC) was calculated to estimate the accumulated changes in the studied PGDP and compared using paired-t test between the KEβHB and placebo beverages.</p></div><div><h3>Results</h3><p>Responders had a significantly greater reduction in plasma glucose compared with non-responders following acute ketosis (p &lt; 0.001). The AUC_0-150 for oxyntomodulin was significantly lower following the KEβHB beverage compared with the placebo (p = 0.045) in responders, but not in non-responders (p = 0.512). No significant differences in AUCs_0-150 were found for GLP-1, glicentin, glucagon, and MPGF in either responders or non-responders.</p></div><div><h3>Conclusion</h3><p>Oxyntomodulin is involved in lowering plasma glucose and may play an important role in diabetes remission.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 6","pages":"Article 103052"},"PeriodicalIF":10.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1871402124001139/pdfft?md5=df629cb76e36655362acf685b2fac292&pid=1-s2.0-S1871402124001139-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141404020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unique metabolomics characteristics for distinguishing cirrhosis related to different liver diseases: A systematic review and meta-analysis","authors":"Liu Yang ,&nbsp;Fang Wang ,&nbsp;Sijia Liu ,&nbsp;Zicheng Xian ,&nbsp;Shenshen Yang ,&nbsp;Yanyan Xu ,&nbsp;Lexin Shu ,&nbsp;Xingxu Yan ,&nbsp;Junjie He ,&nbsp;Xia Li ,&nbsp;Cheng Peng ,&nbsp;Chenghao Bi ,&nbsp;Yu Yuan ,&nbsp;Siyu Chen ,&nbsp;Liwen Han ,&nbsp;Rongrong Yang ,&nbsp;Yubo Li","doi":"10.1016/j.dsx.2024.103068","DOIUrl":"10.1016/j.dsx.2024.103068","url":null,"abstract":"<div><h3>Background and aim</h3><p>Clinical evidence for early identification and diagnosis of liver cirrhosis (LC) caused by different types of liver disease is limited. We investigated this topic through a meta-analysis of quantitative metabolomics.</p></div><div><h3>Methods</h3><p>Four databases were searched until October 31, 2022 for studies comparing metabolite levels between patients with different types of liver disease and control individuals. A random-effects model was applied for the meta-analysis.</p></div><div><h3>Results</h3><p>This study included 55 studies with 8266 clinical participants, covering 348 metabolites. In LC related to drug-induced liver injury (DILI), hepatitis B virus (HBV) infection, and non-alcoholic fatty liver disease (NAFLD), the primary bile acid biosynthesis (taurocholic acid: SMD, 1.08[0.81, 1.35]; P &lt; 0.00001; glycocholic acid: SMD, 1.35[1.07, 1.62]; P &lt; 0.00001; taurochenodeoxycholic acid: SMD, 1.36[0.94, 1.78]; P &lt; 0.00001; glycochenodeoxycholic acid: SMD, 1.49[0.93, 2.06]; P &lt; 0.00001), proline and arginine (<span>l</span>-proline: SMD, 1.06[0.53, 1.58]; P &lt; 0.0001; hydroxyproline: SMD, 0.81[0.30, 1.33]; P = 0.002), and fatty acid biosynthesis (palmitic acid: SMD, 0.44[0.21, 0.67]; P = 0.0002; oleic acid: SMD, 0.46[0.19, 0.73]; P = 0.0008; stearic acid: SMD, 0.37[0.07, 0.68]; P = 0.02) metabolic pathways were significantly altered.</p></div><div><h3>Conclusion</h3><p>We identified key biomarkers and metabolic characteristics for distinguishing and identifying LC related to different types of liver disease, providing a new perspective for early diagnosis, disease monitoring, and precise treatment.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 6","pages":"Article 103068"},"PeriodicalIF":4.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highlights of the current issue","authors":"Ningjian Wang (Associate Editor) ,&nbsp;Anoop Misra (Editor-in-Chief)","doi":"10.1016/j.dsx.2024.103084","DOIUrl":"10.1016/j.dsx.2024.103084","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 6","pages":"Article 103084"},"PeriodicalIF":4.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142128819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of oral semaglutide in type 2 diabetes: A systematic review of real-world evidence","authors":"Awadhesh Kumar Singh ,&nbsp;Ritu Singh ,&nbsp;Akriti Singh ,&nbsp;Anoop Misra","doi":"10.1016/j.dsx.2024.103024","DOIUrl":"https://doi.org/10.1016/j.dsx.2024.103024","url":null,"abstract":"<div><h3>Background and aims</h3><p>Oral semaglutide has undergone global Phase 3 development programs named PIONEER and approved for therapeutic use in people with type 2 diabetes (T2D). We aim to systematically review the efficacy and safety of oral semaglutide in real-world settings.</p></div><div><h3>Methods</h3><p>We systematically searched the electronic databases of PubMed, Google Scholar, and <span>ClinicalTrials.gov</span><svg><path></path></svg> from inception until March 15, 2024, using several keywords with Boolean “AND”. We retrieved all the available granular details of real-world studies (RWS).</p></div><div><h3>Results</h3><p>To date, results from four prospective and ten retrospective real-world studies of oral semaglutide in T2D are available. In prospective studies, the primary outcome of HbA1c reduction varied from −0.9 % to −1.6 %, weight loss varied from −4.7 kg to −8.2 kg and HbA1c target of &lt;7 % was achieved in 30 %–64 % with oral semaglutide. In retrospective studies, HbA1c reduction varied from −0.4 % to −1.8 %, weight reduction varied from −1.4 to −9.0 kg, HbA1c target of &lt;7 % was achieved in 32–64 %, and 30–41 % of people with T2D had ≥5 % weight loss with oral semaglutide. Gastrointestinal adverse events with oral semaglutide varied from 16 % to 50 % in prospective and 6 %–47 % in retrospective RWS. Overall, 0 %–18 % of patients had oral semaglutide discontinuation due to any cause.</p></div><div><h3>Conclusion</h3><p>Oral semaglutide exhibited a reasonable reduction in HbA1c and weight in people with T2D, consistent with the findings from PIONEER trials. While no new safety issues emerged, the inherent limitations of RWS underscore the necessity of long-term investigations to comprehensively assess safety.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 5","pages":"Article 103024"},"PeriodicalIF":10.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140879673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of quitting smoking on diabetes-related complications: A scoping review with a systematic search strategy","authors":"Magdalena Walicka ,&nbsp;Arkadiusz Krysiński ,&nbsp;Giusy Rita Maria La Rosa ,&nbsp;Ang Sun ,&nbsp;Davide Campagna ,&nbsp;Agostino Di Ciaula ,&nbsp;Tabinda Dugal ,&nbsp;Andre Kengne ,&nbsp;Phuong Le Dinh ,&nbsp;Anoop Misra ,&nbsp;Riccardo Polosa ,&nbsp;Syed Abbas Raza ,&nbsp;Cristina Russo ,&nbsp;Roberta Sammut ,&nbsp;Noel Somasundaram ,&nbsp;the DiaSmokeFree Working Group","doi":"10.1016/j.dsx.2024.103044","DOIUrl":"10.1016/j.dsx.2024.103044","url":null,"abstract":"<div><h3>Introduction</h3><p>Smoking in people with diabetes markedly elevates their risk of developing complications and increases the likelihood of cardiovascular mortality. This review is the first to specifically provide evidence-based analysis about the influence of quitting smoking on diabetes-related complications in people with type 2 diabetes.</p></div><div><h3>Method</h3><p>The present review was carried out according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Extension for Scoping Reviews. All human clinical studies assessing the effects of stopping smoking cessation on diabetes-related complications were included. PubMed and Embase were screened until January 2024. References of primary studies and principal peer-reviewed scientific journals in the field were manually screened.</p></div><div><h3>Results</h3><p>We identified a total of 1023 studies. Only 26 met the criteria for eligibility. In general quitting smoking is associated with decreased risks of myocardial infarction and ischemic stroke. Regarding microvascular complications, the strongest evidence for the beneficial effects of smoking cessation is observed in diabetic nephropathy. However, the relationship between smoking cessation and retinopathy, neuropathy, diabetic foot complications and diabetic-related erectile dysfunction, is poorly investigated.</p></div><div><h3>Conclusion</h3><p>Quitting smoking offers significant advantages in managing diabetes-related complications, significantly lowering the risks of myocardial infarction, ischemic stroke, and diabetic nephropathy. This underscores the importance of cessation. Providing evidence-based information on the benefits of stopping smoking for people with type 2 diabetes who smoke, can bolster smoking cessation efforts in the context of diabetes management.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 5","pages":"Article 103044"},"PeriodicalIF":10.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S187140212400105X/pdfft?md5=6457770d98f7f923c13ebbafe09e12a1&pid=1-s2.0-S187140212400105X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141139336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Specific differences and novel key regulatory genes of sex in influencing exceptional longevity phenotypes","authors":"Xiaolin Ni ,&nbsp;Huabin Su ,&nbsp;Gong-Hua Li ,&nbsp;Rongqiao Li ,&nbsp;Rushu Lan ,&nbsp;Yuan Lv ,&nbsp;Guofang Pang ,&nbsp;Wei Zhang ,&nbsp;Ze Yang ,&nbsp;Caiyou Hu","doi":"10.1016/j.dsx.2024.103039","DOIUrl":"10.1016/j.dsx.2024.103039","url":null,"abstract":"<div><h3>Background and aims</h3><p>Although the life expectancy of women systematically and robustly exceeds that of men, specific differences and molecular mechanisms of sex in influencing longevity phenotypes remain largely unknown. Therefore, we performed transcriptome sequencing of peripheral blood samples to explore regulatory mechanisms of healthy longevity by incorporating sex data.</p></div><div><h3>Methods</h3><p>We selected 34 exceptional longevity (age: 98.26 ± 2.45 years) and 16 controls (age: 52.81 ± 9.78) without advanced outcomes from 1363 longevity and 692 controls recruited from Nanning of Guangxi for RNA sequencing 1. The transcriptome sequencing 1 data of 50 samples were compared by longevity and sex to screen differentially expressed genes (DEGs). Then, 121 aging samples (40–110 years old) without advanced outcomes from 355 longevity and 294 controls recruited from Dongxing of Guangxi were selected for RNA sequencing 2. The genes associated with aging from the transcriptome sequencing 2 of 121 aging samples were filtered out. Finally, the gender-related longevity candidate genes and their possible metabolic pathways were verified by cell model of aging and a real-time polymerase chain reaction (RT-PCR).</p></div><div><h3>Results</h3><p>Metabolism differs between male and female and plays a key role in longevity. Moreover, the principal findings of this study revealed a novel key gene, UGT2B11, that plays an important role in regulating lipid metabolism through the peroxisome proliferator activated receptor gamma (PPARG) signalling pathway and ultimately improving lifespan, particularly in females.</p></div><div><h3>Conclusion</h3><p>The findings suggest specific differences in metabolism affecting exceptional longevity phenotypes between the sexes and offer novel therapeutic targets to extend lifespan by regulating lipid homeostasis.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 5","pages":"Article 103039"},"PeriodicalIF":10.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1871402124001000/pdfft?md5=a427c1fe9621d4e7a5e358fa3c729468&pid=1-s2.0-S1871402124001000-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141052645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}